Industry News

- Read more about Religare Wellness is now Fortis Health World and is taking E-commerce by Storm
(Business Wire India); RWL Healthworld Ltd. (formerly known as Religare Wellness) has been re-branded as Fortis Health World; and is successfully running a leading e-commerce portal that sells beauty, wellness and health-care products such as baby care products, face and skin care range, home and living utilities as well as diabetic remedies.
- Read more about Lupin introduce Duloxetine in US
Mumbai based pharma major Lupin Limited announced that its subsidiary Lupin Pharmaceuticals Inc (Lupin) has launched its Duloxetine 40 mg delayed-release (DR) capsule, which is the first and only generic Duloxetine formulation to become available in 40 mg dosage strength.
- Read more about Glenmark Pharma receives US FDA approval for voriconazole tablets
Glenmark Pharmaceuticals Inc., USA (Glenmark) has received final approval from the United States Food & Drug Administration (FDA) for voriconazole tablets, 50 mg and 200 mg of PF Prism C.V. (Prism).
- Read more about Teva launch Zecuity, First Transdermal Patch System, In US to Treat Migraine
Teva Pharmaceutical Industries Ltd launch Zecuity, the first and only patch system in US designed to provide relief from migraine. Zecuity is a single-use, disposable patch system that delivers sumatriptan through the skin. Zecuity is a prescription medicine used for the acute treatment of migraine headaches with or without aura in adults.
- Read more about Sandoz launch biosimilar Zarxio in US market
Sandoz, a Novartis company and a global leader in generic pharmaceuticals launch of first biosimilar Zarxio (filgrastim-sndz). Zarxio is the first biosimilar approved by the US Food and Drug Administration (FDA).
- Read more about Honeywell launch Safyr in India’s Domestic Pharmaceutical Packaging Market
Honeywell, a diversified technology and manufacturing leader, introduced Safyr, a high-moisture barrier thermoformable film designed specifically to meet the requirements of India’s domestic pharmaceutical packaging market.
- Read more about Glenmark’s GBR 830 entered into phase 2 studies in AD and celiac disease in US & Europe
Glenmark Pharmaceuticals S.A., GBR 830, a novel monoclonal antibody has completed clinical phase 1 dosing. GBR 830 is an antagonist of OX40, a costimulatory receptor expressed on T cells mediating T cell activation and survival. Glenmark has now completed clinical phase I studies for GBR 830 in the Netherlands.

[adsense:336x280:8701650588]
- Read more about Amgen and Novartis collaborate for Alzheimer's & migraine treatments
Amgen, a biopharmaceutical company, has entered a neuroscience collaboration with Novartis in the areas of Alzheimer's disease and migraine. The collaboration also enables Amgen to focus on the commercialisation of its migraine programmes in the US, Canada and Japan, while leveraging Novartis' strong commercial capabilities in neuroscience throughout Europe and other markets worldwide.
- Read more about BPL Medical Technologies acquires Penlon Ltd.
BPL Medical Technologies Private Ltd announced the acquisition of Penlon Ltd, a UK-based leading global manufacturer of anaesthesia systems and vaporisers with worldwide distribution networks.
- Read more about Herbalife launches third phase of Casa Herbalife program with smile foundation
(NewsVoir); The Herbalife Family Foundation (HFF), a non-profit organization dedicated to improving the lives of children by helping charitable organizations provide healthy nutrition to children in need, today announced the launch of the third phase of Casa Herbalife program with Smile Foundation, a national development organization that works for underprivileged children and youth in education, healthcare, livelihoods and women’s empowerment. During the third phase unveiled today in Bangalore, the HFF will extend grants to provide nutritional support to 1,000 children across India, through Smile Foundation’s ‘Mission Education’ program.